Nasus Pharma is trading 5.61% down at $3.87, with no new announcement dated August 31, 2026, or reliable report explicitly explaining the decline.
- Latest investor-relations updates were the August 19 CFO transition and August 17 first-half results.
- Those updates are stale catalysts rather than confirmed same-day drivers.
- Broader indexes are lower, but moves remain below the threshold for a clear market-wide explanation.